Baxter/Spectral partnership Spextral Medical announced yesterday in a Conference Call that Baxter had committed to an additional $2M payment to Spectral, at the interim 90 out of 150 patient study for Spectral's FDA trial for treatment of Septic Shock. That is set to wrap up 4Q 2024 approximately. Baxter cut a deal with Spectral last year for use of their Kidney Treatment products, soon to be part of the Vantive IPO.
Do any of the veteran Baxter shareholders have some insights as to how significant this REALLY is to Baxter's future business plans? It just seems that Spectral is just an 'also-ran' to Baxter, given that it is a penny stock on the TSX. Need a little Big Picture, please, from Baxter people.
Safe travels & happy investing,
Mac